Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases Funding led by Seroba Life Sciences and supported by Théa Open Innovation, eureKARE and e... Biopharmaceuticals, Venture Capital Coave Therapeutics, gene therapy, AAV-Ligand Conjugate, ALIGATER
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news